Advocates for Human Potential, Inc.

A Bureau of Justice Assistance (BJA) funded program provided by Advocates for Human Potential, Inc. (AHP)
in partnership with Treatment Alternatives for Safe Communities (TASC) and AdCare Criminal Justice Services (ACJS).


 


Promising Practices Guidelines for Residential Substance Abuse Treatment






Jail-Based Medication-Assisted Treatment









Role of Corrections Officers in Jail/Prison Substance Use Disorder Treatment Programs





Preventing, Detecting and Treating HIV/AIDS and Viral Hepatitis: Health Promotion and Risk/Harm Reduction in Substance Abuse Treatment



A Comprehensive Listing of What States Cover for Substance
Use Disorder, including Medications





New Manual on
Health Literacy

Once they obtain health coverage, RSAT participants need to maximize the benefits offered in terms of preventive and primary care to promote both better physical and behavioral health.







 

Other Prison/Jail MAT Manuals

Kentucky DOC Substance Abuse Medication Assisted Treatment Protocol
Rhode Island Vivitrol Manual
Rhode Island Suboxone SOP
Rhode Island Distribution of Suboxone Protocol
Massachusetts Department of Correction Medication Assisted Treatment Re-Entry Initiative (MATRI) Clinical Guidelines
Vermont MAT for Inmates: Work Group Evaluation Report and Recommendations
New Hampshire DOC MAT and Naltrexone Oral Augmentation Clinical Guidelines
Department of Vermont Health Access, Managed Care Entity, Vermont Buprenorphine Clinical Practice Guidelines, August 2015
Resolution of National Sheriffs’ Association on MAT
ACA and ASAM Joint Policy on OUD Rx in Justice System


Correctional MAT Videos



SAMHSA Video: Benefits and Cost Savings of MAT
Services in a Correctional Setting

This video features presentations from Jon Berge, SAMHSA, Mark Parrino, American Association for the Treatment of Opioid Dependence, Andrew Klein, RSAT TTA and Advocates for Human Potential, Kathleen Maurer, Connecticut DOC, and Kevin Pangburn, Kentucky DOC.


Montgomery County Corrections

Montgomery County, Maryland Department of Correction and Rehabilitation
video on that institution’s MAT Program


Massachusetts Department of Corrections


Brief descriptions of some Prison and Jail MAT Programs

Kentucky Prison, Massachusetts Prison, Philadelphia Jail, Rhode Island Prison,
West Virginia Prison, Wisconsin, Sacramento Jail, New Haven and Bridgeport Jails (Administered by state DOC), Kenton County, Kentucky Jail, Montgomery County, Maryland Jail, Barnstable County, Massachusetts Jail, Middlesex County, New York City Jail, and Salt Lake City Jail


Medication Assisted Treatment Programs In Vermont State Corectional Facilities

This report reviews state correctional MAT programs in VT, MA, NH, MO, RI & KY, and includes the latest cost and recidivism data from most of them.


MASS DOC MATRI PROGRAM


Report on New Hampshire DOC MAT in Custody
Naltrexone Program





"A Rehab Jail for Heroin Addicts" in Franklin County Massachusetts

Franklin County and the Greenfield, Massachusetts community addresses the opioid crisis with an innovative approach to treatment. The Franklin County Jail is one of the only corrections facilities in the country offering suboxone to its clients.



RSAT Jail Program Tour





What Inmates Tell us About RSAT


 

We are offering another round of

PEER HOST SITE TRAININGS in 2019
starting with the Tennessee DOC on April 29-30!
CLICK HERE to download the Host Site Training Description and Application to attend

&
IT'S BACK!!!

RSAT-TTA is joining with the National Criminal Justice Association and International Community Corrections Association for a National Conference!

It will be held from September 15 at 4pm through September 18 at noon. The last morning will be reserved solely for RSAT grantees/attendees. There will be workshops and plenary sessions of interest to RSAT the first three days. Agenda and registration information will be posted soon. Reserve the days! See you in Arlington, VA!

 


  • Wednesday, March 27, 2019

  • Technology in Treating Opioid Use Disorders

  • Click here for webinar information


  • amfAR's Opioid & Health Indicators Database

    This free web platform is designed to support communities, lawmakers and advocates in making informed decisions about the opioid epidemic and its impact on HIV and hepatitis C. It provides local to national statistics using reliable data sources on new HIV and hepatitis C infections, opioid use and overdose death rates, and the availability of services like drug treatment programs and syringe exchange services. In addition, users can examine data at the state or the county levels to see the differential impact of the opioid epidemic by state or within states.

  • Comparative Efficacy and Acceptability of Psychosocial Interventions for Individuals with Cocaine and Amphetamine Addiction

    This meta-analysis is the most comprehensive synthesis of data for psychosocial interventions in individuals with cocaine and/or amphetamine addiction. The findings provide the best evidence base currently available to guide decision-making about psychosocial interventions for individuals with cocaine and/or amphetamine addiction and should inform patients, clinicians, and policy-makers. Researchers used meta-analysis to analyze 50 clinical studies (6,943 participants) on 12 different psychosocial interventions for cocaine and/or amphetamine addiction. They found that the combination of 2 different psychosocial interventions, namely contingency management and community reinforcement approach, were the most efficacious and most acceptable treatment both in the short and long term.

  • Bias Against Agonist Treatment for Incarcerated People Continues

    Responding to Klein’s article in Commonwealth pointing out the real challenges of implementing jail/prison MAT programming, Alcoholism Alcohol Weekly interviews both Klein and a physician involved in the Riker Island New York City jail agonist MAT program to vindicate “mainstream” support for MAT. The latter dismisses low retention rates of persons provided MAT in prison/jail and focuses on forcing people to withdraw from drugs when incarcerated.

  • Medicaid Coverage of Medication-Assisted Treatment for Alcohol and Opioid Use Disorders and of Medication for the Reversal of Opioid Overdose

    This SAMHSA publication details coverage for MAT medications and Naloxone. All states reimburse for at least some of the MAT medications although 8 don’t cover methadone for MAT, just for pain relief. Fewer than 70% cover implant and injectable buprenorphine. Many include certain constraints on obtaining the medication. Some innovative programs are highlighted such as Missouri which has begun the process of integrating MAT into all SUD treatment in the state, requiring any SUD treatment provider that contracts with the state to offer MAT either directly or by referral. The state of Washington has implemented a pilot involving a telemedicine project, Flex Care, so that 200 patients in rural coastal Washington who previously had no access to MAT for their opioid dependence disorder now receive MAT under the Flex Care treatment model.

  • Fentanyl Now The no. 1 Opioid OD Killer

    Although cocaine and heroin remain most popular street drugs, fentanyl is involved in more overdose deaths. Between 2013 and 2016, overdose deaths involving fentanyl increased 113% per year. Over the past several years, heroin and cocaine mixed with fentanyl have become more common, which may account for the combination of drugs seen on death certificates. methamphetamine. In 2011, oxycodone ranked first. From 2012 to 2015, it was heroin, and in 2016, fentanyl. Cocaine consistently was the second or third drug most common in overdoses during the entire period.

  • Prescription Mobile Medical App cleared as component of Opioid Use Disorder Treatment

    The U.S. Food and Drug Administration cleared a mobile medical application (app) to help increase treatment retention in an outpatient program for individuals with opioid use disorder (OUD). The reSET-O app is a prescription cognitive behavioral therapy intended to be used in addition to outpatient treatment under the care of a health care professional, in conjunction with treatment that includes buprenorphine and contingency management. Although reSET-O did not reduce positive drug screens, it did significantly increase treatment retention. Using internet-based or mobile apps in conjunction with treatment for substance use disorders is not a new idea. There are many studies going back over 10 years that have shown promising outcomes in using technology based cognitive-behavioral treatment sessions and/or community reinforcement approach to enhance as well as reduce traditional counselor based treatment sessions. Evidence-based interventions will continue to be designed to improve executive function and be delivered through the use of mobile apps and, coupled with their high program consistency and participant enjoyment, appear to be a logical choice for repairing cognitive dysfunction.

  • Best Practices for Successful Reentry for People Who Have Opioid Addiction

    This new publication from Council of State Government Justice Center outlines major reentry activities. It describes best practices for correction departments, community-based behavioral health agencies, and probation and parole to ensure reentry is safe and successful for people with opioid addictions.

  • Evaluation of Amphetamine-Related Hospitalizations and Associated Clinical Outcomes and Costs in the United States

    Overshadowed by opioids, meth is back with a vengeance. Study finds amphetamine use is skyrocketing in United States. Hospitalizations up 245% from 2008 to 2015. Poses renewed challenge for RSAT programs.

  • MA Jail Ordered to Continue Methadone for Entering Inmate

    Order from Federal District Court requiring Massachusetts jail to continue methadone for individual entering jail for 60 day sentence for operating after suspension. Defendant had failed to remain abstinent on buprenorphine and naltrexone but had succeeded for past two years on methadone. Sheriff had argued that medical detox and in house drug treatment as well as access to naltrexone was sufficient to address defendant’s needs without compromising institutional security by allowing the introduction of methadone the jail was not equipped to dispense.

  • Long Stigmatized, Methadone Clinics Multiply in Some States

    Access to methadone maintenance is growing, but Alabama, Arkansas, Idaho, Illinois, Iowa, Kentucky, Louisiana, Nebraska, North Dakota, South Carolina, Tennessee, Texas and Wyoming do not allow Medicaid reimbursement for methadone treatment. Much lower number of doctors prescribe buprenorphine of opioid addiction than anticipated. Many obtain licenses to prescribe buprenorphine (requires 8 hour course) but treat only existing patients and are not interested in adding new patients with opioid use disorder. This means that jail and prisons that institute MAT programs that provide agonist medications have to do their homework to connect exiting individuals with available methadone clinics or physicians and medical personnel willing to treat them with buprenorphine.

  • Promising Practices Archive


Information on Effective Cognitive Behavioral Approaches


MAT Resources and Research


Substance Abuse Facilities-Opioid Treatment Services,
SAMHSA Feb. 2017

Map of Opioid Treatment Providers

SAMHSA’s Pocket Guide to Medication-assisted Treatment for Opioid Use Disorders

Link to PDF:

http://store.samhsa.gov/shin/content//SMA16-4892PG/SMA16-4892PG.pdf

Link to SAMHSA Store page on this item:

http://store.samhsa.gov/product/Medication-Assisted-Treatment-of-Opioid-Use-Disorder-Pocket-Guide/Most-Popular/SMA16-4892PG?sortByValue=4

FDA Newly Issued ‘Boxed’ warning on the dangers of combining opioids and benzodiazepines

Link to the FDA Drug Safety Announcement:

http://www.fda.gov/Drugs/DrugSafety/ucm518473.htm

Link to PDF of Safety Announcement:

http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf

Tennessee Health Department Finds Some Overdose Deaths Associated With Buprenorphine


Opioid Treatment Drugs Have Similar Outcomes Once Patients Initiate Treatment

This NIDA study compares buprenorphine/naloxone combination to extended release naltrexone. It is the second that now finds the two medications work equally well although one is an opioid substitute and the other an opioid (and alcohol) blocker.

Participate in our forum!

Our RSAT program does a pretty good job including education about overdose prevention and risk reduction, but the beds are limited. We would like to pilot a naloxone distribution program and see if we can expand it for all inmates, not just RSAT participants. Any good models out there so we don't have to reinvent the wheel?